Featured Experience
Artificial Intelligence
In the rapidly evolving world of artificial intelligence (AI), safeguarding your intellectual property (IP) is critical. As a market and thought leader in the technology sector, Sterne Kessler helps clients develop comprehensive IP solutions that protect innovation, foster growth, and maximize value. Whether you are an emerging startup company or a well-established technology pioneer, we are committed to helping you harness the full potential of AI technology.
Pharmaceutical Patent Litigation
At Sterne Kessler, we know what it takes to win across any venue in pharmaceutical IP litigation. Our award-winning team has a deep bench of experienced litigators representing biosimilars as well as generic and specialty brand pharmaceutical companies in high-profile patent litigation, including blockbuster Abbreviated New Drug Application (ANDA) and Biologics Price Competition and Innovation Act (BPCIA) matters.
ITC Litigation
With one of the nation’s top ITC practices, Sterne Kessler offers unrivaled experience, comprehensive litigation strategy, and the legal and technical know-how to achieve the best possible results. In the last five years, Sterne Kessler has handled more cases at the ITC than 90% of firms appearing before the Commission.
Design Patents
For nearly four decades, Sterne Kessler has been at the forefront of design patents, consistently delivering successful outcomes for clients in securing and defending their design rights. We develop effective, comprehensive IP programs to protect some of the most iconic product designs in the world and to eliminate knock-offs in the marketplace.
Featured News
More News & Insights
Happy Holidays from Sterne Kessler
As 2024 draws to a close, we reflect on the spirit of giving. While intellectual property is our passion, we’re also committed to giving back to communities in…
IP Hot Topic: USPTO Establishes New Fees for More Than Fifty Cumulative IDS References
Along with other new and increased fees, including the surcharge for late-stage continuation applications, the United States Patent & Trademark Office published a final rule on November 20,…
Sterne Kessler Secures U.S. International Trade Commission Win for SV3 in Unfair Importation Case Brought by RJ Reynolds
Washington, D.C. (November 19, 2024) – Sterne, Kessler, Goldstein & Fox received a significant ruling in a patent infringement case before the U.S. International Trade Commission (ITC) on…
Sterne Kessler Secures PTAB Victory for Palo Alto Networks against British Telecommunications—All Claims Unpatentable
Sterne, Kessler, Goldstein & Fox secured a final written decision finding all claims unpatentable in an inter partes review at the U.S. Patent and Trademark Office Patent Trial…
Old Drugs, New Tricks: Repurposing Through 505(b)(2) Submissions
Summer Associates Hannah Jankunis and Matthew Swazer also contributed to this article. FDA DRUG APPROVAL PATHWAYS 505(b)(1) New Drug Application De novo drug development is costly and time…
Subject Matter Eligibility of AI Innovations—USPTO’s Updated Guidance
This article discusses the July 17, 2024 guidance[1] issued by the United States Patent and Trademark Office (“USPTO”) regarding the subject matter eligibility of patent claims involving artificial…
Your innovations are worth the best protection
Expertise
Sterne Kessler is a full-service IP firm that delivers innovative solutions tailored to your business and industry.